Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616634 | 0.98 | KCNA3 (0.53) | KCNA3MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL30036856 | 0.97 | KCNA3 (0.47) | KCNA3MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL11484964 | 0.95 | KCNA3 (0.51) | KCNA3MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL11788207 | 0.90 | SLC6A2 (0.45) | KCNA3MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL14640497 | 0.90 | SLC6A2 (0.45) | KCNA3MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL14817427 | 0.89 | KCNA3 (0.48) | KCNA3MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4476845 | 0.88 | KCNA3 (0.47) | KCNA3MEN1KMT2AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL11789965 | 0.87 | SLC6A2 (0.44) | KCNA3MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL852761 | 0.86 | CYP3A4 (0.50) | KCNA3MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29332538 | 0.86 | ESR1 (0.56) | KCNA3MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768307-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-2785178-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-2720539-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20170237926-A1 | OPTICAL DETECTOR AND METHOD FOR MANUFACTURING THE SAME | BASF SE (DE) | 2017-08-17 | — | — | US | disclosed |
| CN-103917093-B | Opsin binding ligands, compositions, and methods of use | 比卡姆药品公司 | 2017-08-11 | — | — | CN | disclosed |
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| CN-106431988-A | Opsin-binding ligands, compositions and methods of use | 比卡姆药品公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170037024-A1 | Opsin-Binding Ligands, Compositions and Methods for Use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2002087508-A2 | NITROSATED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1246621-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | NICOX S.A. (FR) | 2002-08-29 | — | — | US | disclosed |
| WO-2002060378-A2 | SUBSTITUTED ARYL COMPOUNDS AS CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NICOX S.A. (FR) | 2001-11-15 | — | — | US | disclosed |
| WO-2001045703-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-0445749-B1 | N-Monosubstituted cyclopentenylamines, a process for their preparation and their use as medicaments | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-07-10 | — | — | EP | disclosed |
| US-4141993-A | ANTIDEPRESSANTS | ASTRA LAKEMEDEL AKTIEBOLAGET (SE) | 1979-02-27 | — | — | US | disclosed |
| US-4141993-A | ANTIDEPRESSANTS | ASTRA LAKEMEDEL AKTIEBOLAGET (SE) | 1979-02-27 | — | — | US | disclosed |
| US-4053637-A | ANTIDEPRESSANTS | ASTRA LAKEMEDAL AKTIEBOLAG (SW) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | CRYAB, CRYAA, PDE6C | KCNA3 4184/4885MEN1 4794/4885KMT2A 4825/4885 |
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | PTGS2, PTGES2, PTGES | KCNA3 2472/4885MEN1 4707/4885KMT2A 2711/4885 |
| US-20170037024-A1 | Opsin-Binding Ligands, Compositions and Methods for Use | CRYAB, CRYAA, PDE6C | KCNA3 4256/4885MEN1 4799/4885KMT2A 4823/4885 |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | KCNA3 4185/4885MEN1 4774/4885KMT2A 4825/4885 |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | PTGS1, PTGS2, PTGES | KCNA3 2639/4885MEN1 4773/4885KMT2A 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.